Login to Your Account

Clinic Roundup

Monday, October 28, 2013

• Santarus Inc., of San Diego, said based on data from its Phase I study testing SAN-300, an antibody designed to inhibit very late antigen-1, the firm will initiate a placebo-controlled, multiple-ascending-dose Phase IIa trial with subcutaneous administration in patients with active rheumatoid arthritis. The study is slated to start this quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription